As glucagon-like peptide-1 (GLP-1) receptor agonists become increasingly popular medications used to treat both type 2 diabetes and obesity, the question is raised: How do GLP-1s impact kidney health?

The novel care model will integrate FDA-approved kidneyintelX.dkd™ and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, ...

Kidney Health Australia (KHA) has released a report that predicts that the number of people needing treatment for serious kidney disease will triple to 30,000 by 2020 and treating serious kidney ...

In this Ask The Professor Q&A, David St-Jules, a registered dietitian and assistant professor in the Department of Nutrition, and Dr. John Westhoff, associate professor in the School of Medicine and ...

For a disease afflicting 35.5 million people in the U.S., chronic kidney disease flies under the radar. Only half the people who have it are formally diagnosed. The consequences of advanced chronic ...

Kidney disease releases toxins that damage the heart, increasing heart failure risk. “Heart failure and kidney disease are very, very closely intertwined conditions,” said Dr. Rangaswami. Research may ...

While kidney complications are not always front of mind for people living with inflammatory bowel disease (IBD), they are more common than in the general population. From kidney stones to ...

By integrating Renalytix's FDA-approved kidneyintelX.dkd test, the gold standard in predicting progressive decline in kidney function in patients with type 2 diabetes and early-stage CKD, with Carna ...